Anna B Moseley (Anna Moseley)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 13

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Leukemia & lymphoma

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of the National Cancer Institute

This page only lists publications with an associated author ORCID identifier.

Publications

Guillermo Garcia Manero, Nikolai A Podoltsev, Megan K D Othus, John M Pagel, Jerald P Radich, Min Fang, David A Rizzieri, Guido Marcucci, Stephen A Strickland, Mark R Litzow, M Lynn Savoie, Bruno C Medeiros, Mikkael A Sekeres, Tara L Lin, Geoffrey L Uy, Bayard L Powell, Jonathan E Kolitz, Richard A Larson, Richard M Stone, David F Claxton, James Essell, Selina M Luger, Sanjay R Mohan, Anna B Moseley, Frederick R Appelbaum, Harry P Erba
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia (2023)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma 64 (2) (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma 64 (2) (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma 64 (2) (2022)
Anjali S Advani, Anna B Moseley, Kristen M O'Dwyer, Brent L Wood, Min Fang, Matthew J Wieduwilt, Ibrahim Aldoss, Jae H Park, Rebecca B Klisovic, Maria R Baer, Wendy Stock, Rupali R Bhave, Megan K D Othus, Richard C Harvey, Cheryl L Willman, Mark R Litzow, Richard M Stone, Elad Sharon, Harry P Erba
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (14) (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma 64 (2) (2022)
Dawn L Hershman, Alfred I Neugut, Anna B Moseley, Kathryn B Arnold, Julie R Gralow, Norah L Henry, Grace Clarke Hillyer, Scott D Ramsey, Joseph M Unger
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. Journal of the National Cancer Institute 113 (8) (2022)
Sarit Assouline, Laura C Michaelis, Megan Othus, Annette E Hay, Roland B Walter, Meagan A Jacoby, Mark A Schroeder, Geoffrey L Uy, Lisa Y Law, Faisal Cheema, Kendra L Sweet, Adam S Asch, Jijun Jane Liu, Anna B Moseley, Tracy Maher, Laura L Kingsbury, Min Fang, Jerald Radich, Richard F Little, Harry P Erba
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma 64 (2) (2022)
Anjali S Advani, Anna B Moseley, Kristen M O'Dwyer, Brent L Wood, Jae H Park, Matthew J Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron T Gerds, Susan M O'Brien, Jane L Liesveld, Megan Othus, Mark R Litzow, Richard M Stone, Elad Sharon, Harry P Erba
Dasatinib/Prednisone Induction Followed by Blinatumomab/Dasatinib in Ph+ Acute Lymphoblastic Leukemia. Blood advances (2022)
Anna B Moseley, Megan Othus, Guillermo Garcia-Manero, Frederick R Appelbaum, Harry P Erba, Roland B Walter
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. Leukemia & lymphoma 62 (7) (2021)
Joseph M Unger, Anna B Moseley, Christabel K Cheung, Raymond U Osarogiagbon, Banu Symington, Scott D Ramsey, Dawn L Hershman
Persistent Disparity: Socioeconomic Deprivation and Cancer Outcomes in Patients Treated in Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)